Hvivo PLC (LON:HVO) insider James Winschel acquired 6,420 shares of the stock in a transaction that occurred on Monday, October 8th. The shares were bought at an average cost of GBX 62 ($0.81) per share, with a total value of £3,980.40 ($5,201.10).
Shares of LON:HVO traded up GBX 5 ($0.07) during mid-day trading on Monday, reaching GBX 63.50 ($0.83). 198,213 shares of the company were exchanged, compared to its average volume of 49. Hvivo PLC has a 1 year low of GBX 50 ($0.65) and a 1 year high of GBX 136.89 ($1.79).
HVO has been the subject of a number of research analyst reports. Numis Securities reaffirmed a “buy” rating and set a GBX 55 ($0.72) price objective on shares of Hvivo in a research report on Monday, June 18th. Barclays raised shares of Hvivo to an “overweight” rating in a research report on Wednesday, September 19th.
hVIVO plc, a specialty biopharma company, provides medical and scientific research services in the United Kingdom, the United States, and Europe. The company is developing a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases, including influenza virus, respiratory syncytial virus, asthma exacerbation, and human rhinovirus.
Featured Story: Call Option
Receive News & Ratings for Hvivo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hvivo and related companies with MarketBeat.com's FREE daily email newsletter.